Solid Biosciences Inc. 8-K

What Happened

• Solid Biosciences Inc. held its Annual Meeting of Stockholders on June 10, 2026 and reported the voting results in an 8-K. Shareholders approved an amendment to increase authorized common shares from 240,000,000 to 480,000,000, and the Company filed a Certificate of Amendment with the Delaware Secretary of State the same day.
• Stockholders also elected Clare Kahn, Adam Stone and Lynne Sullivan as Class II directors (terms to 2029), ratified Ilan Ganot as a Class I director (advisory basis) to 2028, ratified PricewaterhouseCoopers LLP as independent auditor for fiscal 2026, and approved the non-binding advisory vote on executive compensation (say-on-pay).

Key Details

• Share increase amendment: 85,604,508 For; 893,360 Against; 27,502 Abstain. Certificate of Amendment filed June 10, 2026.
• Director elections (Class II, terms to 2029): Clare Kahn — 73,139,200 For; 5,700,169 Withheld; Adam Stone — 71,556,735 For; 7,282,634 Withheld; Lynne Sullivan — 73,124,331 For; 5,715,038 Withheld. (Broker non-votes: 7,685,551.)
• Ilan Ganot ratification (advisory) as Class I director: 78,636,398 For; 185,585 Against; 17,386 Abstain; 7,685,551 Broker non-votes.
• PwC ratified as auditor for 2026: 86,420,186 For; 70,007 Against; 34,727 Abstain.
• Say-on-pay (advisory): 72,596,980 For; 6,203,634 Against; 38,755 Abstain; 7,685,551 Broker non-votes.

Why It Matters

• The approved increase in authorized common shares doubles the Company’s capacity to issue stock. That can enable future financings, acquisitions or equity compensation but also creates potential for dilution if new shares are issued.
• Re-election of the board and ratification of the auditor provide continuity in governance and financial oversight.
• The advisory votes (director ratification in Ilan Ganot’s case and say-on-pay) are non-binding but signal shareholder sentiment on management, board composition and executive compensation.